540 related articles for article (PubMed ID: 29217739)
1.
Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
[TBL] [Abstract][Full Text] [Related]
3. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
[TBL] [Abstract][Full Text] [Related]
4. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival.
Biederman DM; Titano JJ; Lee KM; Pierobon ES; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Tabori NE; Nowakowski FS; Kim E
J Vasc Interv Radiol; 2015 Nov; 26(11):1630-8. PubMed ID: 26321014
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
Kulik LM; Carr BI; Mulcahy MF; Lewandowski RJ; Atassi B; Ryu RK; Sato KT; Benson A; Nemcek AA; Gates VL; Abecassis M; Omary RA; Salem R
Hepatology; 2008 Jan; 47(1):71-81. PubMed ID: 18027884
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.
Memon K; Kulik L; Lewandowski RJ; Mulcahy MF; Benson AB; Ganger D; Riaz A; Gupta R; Vouche M; Gates VL; Miller FH; Omary RA; Salem R
J Hepatol; 2013 Jan; 58(1):73-80. PubMed ID: 23000237
[TBL] [Abstract][Full Text] [Related]
8. Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus.
Cardarelli-Leite L; Chung J; Klass D; Marquez V; Chou F; Ho S; Walton H; Lim H; Tae Wan Kim P; Hadjivassiliou A; Liu DM
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):411-422. PubMed ID: 31909439
[TBL] [Abstract][Full Text] [Related]
9. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
Ali R; Gabr A; Abouchaleh N; Al Asadi A; Mora RA; Kulik L; Abecassis M; Riaz A; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Feb; 41(2):260-269. PubMed ID: 28879621
[TBL] [Abstract][Full Text] [Related]
10. Resin Versus Glass Microspheres for
Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
[TBL] [Abstract][Full Text] [Related]
11. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization.
Memon K; Kulik LM; Lewandowski RJ; Wang E; Wang J; Ryu RK; Hickey R; Vouche M; Baker T; Ganger D; Gates VL; Habib A; Mulcahy MF; Salem R
J Vasc Interv Radiol; 2014 Jul; 25(7):1056-66. PubMed ID: 24613269
[TBL] [Abstract][Full Text] [Related]
13. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
14. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
Salem R; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Ibrahim S; Atassi B; Baker T; Gates V; Miller FH; Sato KT; Wang E; Gupta R; Benson AB; Newman SB; Omary RA; Abecassis M; Kulik L
Gastroenterology; 2010 Jan; 138(1):52-64. PubMed ID: 19766639
[TBL] [Abstract][Full Text] [Related]
15. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
[TBL] [Abstract][Full Text] [Related]
17. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
18. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
20. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS
Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]